The analysis of cell-free DNA (cfDNA) biomarkers using next-generation sequencing (NGS) is becoming increasingly important in cancer research due to its potential applications in early cancer detection, therapy selection, and minimal residual disease (MRD) monitoring. However, there are several challenges that need to be addressed in order to ensure accurate and reliable analysis of cfDNA. In this context, the use of NGS-based assays can provide high sensitivity and specificity in detecting low-level mutations in cfDNA. The success of NGS-based cfDNA analysis depends on several analytical considerations including overcoming sequencing reaction errors, enrichment biases and false positives to detect variant alleles down to 0.1% frequency.  
 
In this webinar, you will learn about  

• The value of cfDNA in cancer research 
• The challenges associated with cfDNA analysis, and  
• Analytical considerations for NGS-based cfDNA biomarker analysis